References
- 1. BAIGENT C, KEECH A, KEARNEY PM, BLACKWELL L, BUCK G, POLLICINO C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 2005; 366:1267–1278.
- 2. SHEPHERD J, COBBE SM, FORD I, ISLES CG, LARIMER AR, MACFARLANE PW, et al., for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Engl J Med 1995; 333:1301–7.
- 3. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Group. Lancet 1994; 344:1383–9.
- 4. KOLOVOU G. The treatment of coronary heart disease. An update. Part 3: Statins beyond cholesterol lowering. Current Med Res and Opinion 2001; 17:34–7.
- 5. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339(19):1349–1357.
- 6. BRADFORD RH, SHEAR CL, CHREMOS AN, DUJOVNE CA, FRANKLIN FA, GRILLO RB, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up. Am J Cardiol 1994; 74(7):667–673.
- 7. STEINHAGEN-THIESSEN E. Comparative efficacy and tolerability of 5 and 10 mg simvastatin and 10 mg pravastatin in moderate primary hypercholesterolemia. Simvastatin Pravastatin European Study Group. Cardiology 1994; 85(3–4):244–254.
- 8. BERTOLINI S, BON GB, CAMPBELL LM, FARNIER M, LANGAN J, MAHLA G, et al. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis 1997; 130(1–2):191–197.
- 9. ARMITAGE J. The safety of statins in clinical practice. Lancet 2007; 370:1781–1790.
- 10. SILVA MA, SWANSON AC, GANDHI PJ, TATARONIS GR. Statin related adverse events: A meta-analysis. Clin Ther. 2006; 28:26-35.
- 11. SILVA M, MATTHEWS ML, JARVIS C, NOLAN NM, BELLIVEAU P, MALLOY M, et al. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther. 2007; 29(2):253-60.
- 12. THOMPSON PD, CLARKSON P, KARAS RH. Statin-associated myopathy. JAMA 2003; 289(13):1681–1690.
- 13. PASTERNAK RC, SMITH SC JR, BAIREY-MERZ CN, GRUNDY SM, CLEEMAN JI, LENFANT C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002; 40:567–572.
- 14. KASHANI A, PHILLIPS CO, FOODY JM, WANG Y, MANGALMURTI S, KO DT, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006; 114:2788–2797.
- 15. DE SAUVAGE NOLTING PR, BUIRMA RJ, HUTTEN BA, KASTELEIN JJ. Two-year efficacy and safety of simvastatin 80 mg in familial hypercholesterolemia (the Examination of Probands and Relatives in Statin Studies with Familial Hypercholesterolemia [ExPRESS FH]). Am J Cardiol 2002; 90:181–184.
- 16. FRANC S, DEJAGER S, BRUCKERT E, CHAUVENET M, GIRAL P, TURPIN G. A comprehensive description of muscle symptoms associated with lipid-lowering drugs. Cardiovasc Drugs Ther 2003; 17:459–465.
- 17. GRAHAM DJ, STAFFA JA, SHATIN D, ANDRADE SE, SCHECH SD, LA GRENADE L, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004; 292(21): 2585–2590.
- 18. The SEARCH Collaborative Group. SLCO1B1 variants and statin induced myopathy – a genomwide study. N Engl J Med 2008; 359(8):789–799.
- 19. SINZINGER H, WOLFRAM R, PESKAR BA. Muscular side effects of statins. J Cardiovasc Pharmacol. 2002; 40(2):163-71.
- 20. FERNANDEZ G, SPATZ ES, JABLECKI C, PHILLIPS PS. Statin myopathy: a common dilemma not reflected in clinical trials. Cleve Clin J Med. 2011; 78(6):393-403.
- 21. NAKAI A, NISHIKOTA M, UCHIDA T, ICHIKAWA M, METSUYAMA K. Enhanced myopathy following administration of hypolipidemic agents under methane anesthesia. Chem Pharm Bull 997; 20:104–6.
- 22. ROWAN CG, BRUNELLI SM, MUNSON J, FLORY J, REESE PP, HENNESSY S, et al. Clinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in The Health Improvement Network. Pharmacoepidemiol Drug Saf. 2012; 21(5):494-506.
- 23. BALLANTYNE CM, CORSINI A, DAVIDSON MH, HOLDAAS H, JACOBSON TA, LEITERSDORF E, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003; 163(5):553-64.
- 24. DUGUÉ A, BAGHERI H, LAPEYRE-MESTRE M, TOURNAMILLE JF, SAILLER L, DEDIEU G, et al. Detection and incidence of muscular adverse drug reactions: a prospective analysis from laboratory signals. Eur J Clin Pharmacol. 2004; 60(4):285-92.
- 25. BRUCKERT E, HAYEM G, DEJAGER S, YAU C, BÉGAUD B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients – the PRIMO study. Cardiovasc Drugs Ther. 2005; 19(6):403-14.
- 26. MOSSHAMMER D, LORENZ G, MEZNARIC S, SCHWARZ J, MUCHE R, MÖRIKE K. Statin use and its association with musculoskeletal symptoms--a cross-sectional study in primary care settings. Fam Pract. 2009; 26(2):88-95.
- 27. HEDENMALM K, ALVAN G, OHAGEN P, DAHL ML. Muscle toxicity with statins. Pharmacoepidemiol Drug Saf. 2010; 19(3):223-31.
- 28. PHILLIPS PS, HAAS RH, BANNYKH S, HATHAWAY S, GRAY NL, KIMURA BJ, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med. 2002; 137(7):581-5.
- 29. CORSINI A. Statin-related muscle complaints: an underestimated risk. Cardiovasc Drugs Ther. 2005; 19(6):379-81.
- 30. GAIST D, RODRÍGUEZ LA, HUERTA C, HALLAS J, SINDRUP SH. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology 2001; 12(5):565-9.